DK4226941T3 - Pegylerede liposomer til levering af immunogen-kodende rna - Google Patents
Pegylerede liposomer til levering af immunogen-kodende rna Download PDFInfo
- Publication number
- DK4226941T3 DK4226941T3 DK23179901.6T DK23179901T DK4226941T3 DK 4226941 T3 DK4226941 T3 DK 4226941T3 DK 23179901 T DK23179901 T DK 23179901T DK 4226941 T3 DK4226941 T3 DK 4226941T3
- Authority
- DK
- Denmark
- Prior art keywords
- immunogen
- delivery
- encoding rna
- pegylated liposomes
- pegylated
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37882610P | 2010-08-31 | 2010-08-31 | |
| EP22188690.6A EP4101462A1 (en) | 2010-08-31 | 2011-08-31 | Pegylated liposomes for delivery of immunogen-encoding rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4226941T3 true DK4226941T3 (da) | 2024-12-02 |
Family
ID=44653554
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21207859.6T DK3970742T3 (da) | 2010-08-31 | 2011-08-31 | Pegylerede liposomer til afgivelse af RNA, der koder immunogen |
| DK22174931.0T DK4066856T3 (da) | 2010-08-31 | 2011-08-31 | Pegylerede liposomer til afgivelse af immunogen-kodende RNA |
| DK21205422.5T DK3981427T3 (da) | 2010-08-31 | 2011-08-31 | Pegylerede liposomer til afgivelse af immunogen-kodende RNA |
| DK22174779.3T DK4066855T3 (da) | 2010-08-31 | 2011-08-31 | Pegylerede liposomer til forsyning af RNA, der koder for immunogen |
| DK23179901.6T DK4226941T3 (da) | 2010-08-31 | 2011-08-31 | Pegylerede liposomer til levering af immunogen-kodende rna |
| DK11758014.2T DK2611461T3 (da) | 2010-08-31 | 2011-08-31 | Pegylerede liposomer til afgivelse af RNA, der koder immunogen |
| DK22174932.8T DK4066857T3 (da) | 2010-08-31 | 2011-08-31 | Pegylerede liposomer til afgivelse af immunogen-kodende RNA |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21207859.6T DK3970742T3 (da) | 2010-08-31 | 2011-08-31 | Pegylerede liposomer til afgivelse af RNA, der koder immunogen |
| DK22174931.0T DK4066856T3 (da) | 2010-08-31 | 2011-08-31 | Pegylerede liposomer til afgivelse af immunogen-kodende RNA |
| DK21205422.5T DK3981427T3 (da) | 2010-08-31 | 2011-08-31 | Pegylerede liposomer til afgivelse af immunogen-kodende RNA |
| DK22174779.3T DK4066855T3 (da) | 2010-08-31 | 2011-08-31 | Pegylerede liposomer til forsyning af RNA, der koder for immunogen |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11758014.2T DK2611461T3 (da) | 2010-08-31 | 2011-08-31 | Pegylerede liposomer til afgivelse af RNA, der koder immunogen |
| DK22174932.8T DK4066857T3 (da) | 2010-08-31 | 2011-08-31 | Pegylerede liposomer til afgivelse af immunogen-kodende RNA |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20130202684A1 (da) |
| EP (11) | EP4226941B1 (da) |
| JP (1) | JP5911870B2 (da) |
| CN (1) | CN103179984A (da) |
| AU (1) | AU2011295935B2 (da) |
| BR (1) | BR112013004866A2 (da) |
| CA (1) | CA2809851A1 (da) |
| CY (3) | CY1125209T1 (da) |
| DK (7) | DK3970742T3 (da) |
| ES (7) | ES2913791T3 (da) |
| FI (3) | FI4066857T3 (da) |
| HR (7) | HRP20220835T8 (da) |
| HU (7) | HUE058361T2 (da) |
| LT (7) | LT4066856T (da) |
| MX (1) | MX2013002336A (da) |
| PL (7) | PL3970742T3 (da) |
| PT (7) | PT4226941T (da) |
| RS (6) | RS63367B1 (da) |
| RU (1) | RU2013114362A (da) |
| SI (7) | SI4066857T1 (da) |
| SM (6) | SMT202200497T1 (da) |
| WO (1) | WO2012031043A1 (da) |
Families Citing this family (272)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| SI2591114T1 (sl) | 2010-07-06 | 2016-10-28 | Glaxosmithkline Biologicals S.A. | Imunizacija velikih sesalcev z majhnimi odmerki RNA |
| AU2011276234B2 (en) | 2010-07-06 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Liposomes with lipids having an advantageous pKa- value for RNA delivery |
| US11291635B2 (en) | 2010-07-06 | 2022-04-05 | Glaxosmithkline Biological Sa | Virion-like delivery particles for self-replicating RNA molecules |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012031043A1 (en) | 2010-08-31 | 2012-03-08 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| BR112013004879A2 (pt) | 2010-08-31 | 2018-04-24 | Novartis Ag | lipossomas pequenos para entrega de rna que codifica imunogénio |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| EP3520813B1 (en) | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| EP4014966A1 (en) * | 2011-07-06 | 2022-06-22 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| EP3854413A1 (en) * | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| SG11201400250UA (en) | 2011-08-31 | 2014-03-28 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| CN108949772A (zh) | 2012-04-02 | 2018-12-07 | 现代泰克斯公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| WO2014028429A2 (en) | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| WO2014108515A1 (en) | 2013-01-10 | 2014-07-17 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof |
| JP2016504050A (ja) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
| EP3608308B1 (en) | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US11155572B2 (en) | 2013-03-15 | 2021-10-26 | Glaxosmithkline Biologicals Sa | RNA purification methods |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| HUE056760T2 (hu) | 2013-07-11 | 2022-03-28 | Modernatx Inc | A CRISPR-hez kapcsolódó fehérjéket és a szintetikus SGRNS-ket kódoló szintetikus polinukleotidokat tartalmazó készítmények és felhasználási módjaik |
| US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| CN106103731A (zh) * | 2013-12-27 | 2016-11-09 | 特洛雷根公司 | 用于在体内向细胞提供活性端粒酶的组合物和方法 |
| US10279047B2 (en) | 2014-01-20 | 2019-05-07 | University Of Utah Research Foundation | Compositions and methods for modifying the surface of cells and methods of use |
| WO2015144732A2 (en) | 2014-03-25 | 2015-10-01 | Yale University | Uses of parasite macrophage migration inhibitory factors |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
| IL316479A (en) | 2014-06-25 | 2024-12-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle compositions for nucleic acid delivery |
| EP3169693B1 (en) | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimeric polynucleotides |
| WO2016014846A1 (en) | 2014-07-23 | 2016-01-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of intrabodies |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| EP3283059B1 (en) | 2015-04-13 | 2024-01-03 | CureVac Manufacturing GmbH | Method for producing rna compositions |
| HUE067372T2 (hu) | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| RS63030B1 (sr) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
| EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| MD3718565T2 (ro) * | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
| AU2016342376A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| WO2017070601A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
| RS63986B1 (sr) | 2015-10-28 | 2023-03-31 | Acuitas Therapeutics Inc | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| CA3007955A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Lipid nanoparticles for delivery of therapeutic agents |
| JP7114465B2 (ja) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
| WO2017112943A1 (en) | 2015-12-23 | 2017-06-29 | Modernatx, Inc. | Methods of using ox40 ligand encoding polynucleotides |
| WO2017120612A1 (en) | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| IL263030B2 (en) | 2016-05-16 | 2024-11-01 | Access To Advanced Health Inst | Pegylated liposomes and methods of use |
| JP7088911B2 (ja) | 2016-05-18 | 2022-06-21 | モデルナティエックス インコーポレイテッド | リラキシンをコードするポリヌクレオチド |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| US10967057B2 (en) | 2016-06-02 | 2021-04-06 | Glaxosmithkline Biologicals S.A. | Zika viral antigen constructs |
| CA3025812A1 (en) | 2016-08-19 | 2018-02-22 | Curevac Ag | Rna for cancer therapy |
| EP3518966A1 (en) | 2016-09-29 | 2019-08-07 | GlaxoSmithKline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
| AU2017345766A1 (en) | 2016-10-21 | 2019-05-16 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| BE1025121B1 (fr) | 2016-11-17 | 2018-11-05 | Glaxosmithkline Biologicals Sa | Constructions antigeniques du virus zika |
| EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
| US11542490B2 (en) | 2016-12-08 | 2023-01-03 | CureVac SE | RNAs for wound healing |
| EP3808380A1 (en) | 2016-12-08 | 2021-04-21 | CureVac AG | Rna for treatment or prophylaxis of a liver disease |
| WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| US11464847B2 (en) | 2016-12-23 | 2022-10-11 | Curevac Ag | Lassa virus vaccine |
| EP3576780A1 (en) * | 2017-02-01 | 2019-12-11 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| WO2018151816A1 (en) | 2017-02-16 | 2018-08-23 | Modernatx, Inc. | High potency immunogenic compositions |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| ES3020935T3 (en) | 2017-03-15 | 2025-05-23 | Modernatx Inc | Lipid nanoparticle formulation |
| MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
| CA3056133A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| KR20190132405A (ko) | 2017-03-15 | 2019-11-27 | 모더나티엑스, 인크. | 치료제의 세포내 전달을 위한 화합물 및 조성물 |
| US20200085944A1 (en) | 2017-03-17 | 2020-03-19 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
| WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| CN110914433A (zh) | 2017-03-24 | 2020-03-24 | 库尔维科公司 | 编码crispr相关蛋白质的核酸及其用途 |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| TW201907937A (zh) | 2017-05-08 | 2019-03-01 | 美商葛利史東腫瘤科技公司 | 阿爾法病毒新抗原載體 |
| US11421011B2 (en) | 2017-05-18 | 2022-08-23 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| ES2952779T3 (es) | 2017-05-18 | 2023-11-06 | Modernatx Inc | ARN mensajero modificado que comprende elementos de ARN funcionales |
| GB2600654B (en) | 2017-05-30 | 2022-11-02 | Glaxosmithkline Biologicals Sa | Novel devices |
| WO2018220553A1 (en) * | 2017-05-30 | 2018-12-06 | Glaxosmithkline Biologicals Sa | Methods for manufacturing a liposome encapsulated rna |
| WO2018222890A1 (en) | 2017-05-31 | 2018-12-06 | Arcturus Therapeutics, Inc. | Synthesis and structure of high potency rna therapeutics |
| EP3638292A1 (en) | 2017-06-14 | 2020-04-22 | ModernaTX, Inc. | Polynucleotides encoding coagulation factor viii |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| BR112019028280A2 (pt) | 2017-07-04 | 2020-07-14 | Curevac Ag | moléculas de ácido nucleico |
| US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| WO2019053012A1 (en) | 2017-09-13 | 2019-03-21 | Biontech Rna Pharmaceuticals Gmbh | RNA REPLICON FOR THE REPROGRAMMING OF SOMATIC CELLS |
| US20200283497A1 (en) | 2017-09-13 | 2020-09-10 | Biontech Cell & Gene Therapies Gmbh | Rna replicon for expressing at cell receptor or an artificial t cell receptor |
| US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
| EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| SG11202002186VA (en) | 2017-10-19 | 2020-05-28 | Curevac Ag | Novel artificial nucleic acid molecules |
| US20210236644A1 (en) | 2017-11-10 | 2021-08-05 | Cocoon Biotech Inc. | Ocular applications of silk-based products |
| JP7424976B2 (ja) | 2017-11-22 | 2024-01-30 | モダーナティエックス・インコーポレイテッド | プロピオン酸血症の治療用のプロピオニルＣｏＡカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド |
| EP3714048B1 (en) | 2017-11-22 | 2025-04-09 | ModernaTX, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
| WO2019104160A2 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
| SG11202005792RA (en) | 2017-12-20 | 2020-07-29 | Vlp Therapeutics Llc | Alphavirus replicon particle |
| JP7653013B2 (ja) | 2018-01-04 | 2025-03-28 | アイコニック セラピューティクス リミテッド ライアビリティ カンパニー | 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法 |
| EP3735270A1 (en) | 2018-01-05 | 2020-11-11 | Modernatx, Inc. | Polynucleotides encoding anti-chikungunya virus antibodies |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| EP3773745A1 (en) | 2018-04-11 | 2021-02-17 | ModernaTX, Inc. | Messenger rna comprising functional rna elements |
| US20210346306A1 (en) | 2018-05-23 | 2021-11-11 | Modernatx, Inc. | Delivery of dna |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| CN113164584A (zh) | 2018-08-17 | 2021-07-23 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物及其用途 |
| WO2020047201A1 (en) | 2018-09-02 | 2020-03-05 | Modernatx, Inc. | Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency |
| EP3849595B1 (en) | 2018-09-13 | 2025-11-19 | ModernaTX, Inc. | Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease |
| WO2020056155A2 (en) | 2018-09-13 | 2020-03-19 | Modernatx, Inc. | Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease |
| US20220401584A1 (en) | 2018-09-14 | 2022-12-22 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| IL281615B2 (en) | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| EP3856233A1 (en) | 2018-09-27 | 2021-08-04 | Modernatx, Inc. | Polynucleotides encoding arginase 1 for the treatment of arginase deficiency |
| US12583816B2 (en) | 2018-10-18 | 2026-03-24 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| WO2020097409A2 (en) | 2018-11-08 | 2020-05-14 | Modernatx, Inc. | Use of mrna encoding ox40l to treat cancer in human patients |
| WO2020109365A1 (en) | 2018-11-29 | 2020-06-04 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020144295A1 (en) | 2019-01-10 | 2020-07-16 | Biontech Rna Pharmaceuticals Gmbh | Localized administration of rna molecules for therapy |
| JP7523449B2 (ja) | 2019-01-11 | 2024-07-26 | アクイタス セラピューティクス インコーポレイテッド | 活性剤の脂質ナノ粒子送達のための脂質 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| EP3930683A1 (en) | 2019-03-01 | 2022-01-05 | Flagship Pioneering Innovations VI, LLC | Compositions, methods, and kits for delivery of polyribonucleotides |
| US20220142896A1 (en) | 2019-03-01 | 2022-05-12 | Flagship Pioneering Innovations Vi, Llc | Polyribonucleotides and cosmetic uses thereof |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| CN114375190A (zh) | 2019-05-08 | 2022-04-19 | 阿斯利康(瑞典)有限公司 | 用于皮肤和伤口的组合物及其使用方法 |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| US20220387628A1 (en) | 2019-06-24 | 2022-12-08 | Modernatx, Inc. | Messenger rna comprising functional rna elements and uses thereof |
| WO2020263883A1 (en) | 2019-06-24 | 2020-12-30 | Modernatx, Inc. | Endonuclease-resistant messenger rna and uses thereof |
| EP4414002B1 (en) | 2019-07-18 | 2026-05-13 | Institut National de la Santé et de la Recherche Médicale | Rac2 g12v mutant for use in ablating hematopoiesis and in the treatment of hematopoietic malignancies |
| CN114206909A (zh) | 2019-07-21 | 2022-03-18 | 葛兰素史克生物有限公司 | 治疗性病毒疫苗 |
| EP4021407A1 (en) | 2019-08-30 | 2022-07-06 | GlaxoSmithKline Biologicals S.A. | Jet mixing lipid nanoparticle manufacturing process |
| MX2022003269A (es) | 2019-09-19 | 2022-07-04 | Modernatx Inc | Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos. |
| CA3155015A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| AU2020352552A1 (en) | 2019-09-23 | 2022-03-17 | Omega Therapeutics, Inc. | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression |
| CN114391040A (zh) | 2019-09-23 | 2022-04-22 | 欧米茄治疗公司 | 用于调节载脂蛋白b(apob)基因表达的组合物和方法 |
| EP3819377A1 (en) | 2019-11-08 | 2021-05-12 | Justus-Liebig-Universität Gießen | Circular rna and uses thereof for inhibiting rna-binding proteins |
| CN114980920A (zh) | 2019-11-18 | 2022-08-30 | 詹森生物科技公司 | 基于突变体calr和jak2的疫苗及其用途 |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| CA3171231A1 (en) | 2020-03-09 | 2021-09-16 | Sean Michael Sullivan | Compositions and methods for inducing immune responses |
| WO2021183720A1 (en) | 2020-03-11 | 2021-09-16 | Omega Therapeutics, Inc. | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression |
| WO2021195218A1 (en) | 2020-03-24 | 2021-09-30 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
| AU2021244555A1 (en) | 2020-03-24 | 2022-11-24 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing factor ix therapeutics |
| EP4135761A1 (en) | 2020-04-16 | 2023-02-22 | GlaxoSmithKline Biologicals S.A. | Sars cov-2 spike protein construct |
| EP4153223A1 (en) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Immunogenic compositions and uses thereof |
| CA3184474A1 (en) | 2020-06-01 | 2021-12-09 | Modernatx, Inc. | Phenylalanine hydroxylase variants and uses thereof |
| EP4162034A1 (en) | 2020-06-04 | 2023-04-12 | BioNTech SE | Rna replicon for versatile and efficient gene expression |
| US20230234992A1 (en) | 2020-06-05 | 2023-07-27 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| WO2022002783A1 (en) | 2020-06-29 | 2022-01-06 | Glaxosmithkline Biologicals Sa | Adjuvants |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| JP7798855B2 (ja) | 2020-07-16 | 2026-01-14 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子に使用するためのカチオン性脂質 |
| WO2022023284A1 (en) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| EP4192496A4 (en) | 2020-08-06 | 2025-01-01 | Gritstone bio, Inc. | MULTIEPITOP VACCINE CASSETTES |
| CN116171150A (zh) | 2020-08-14 | 2023-05-26 | 阿克丘勒斯治疗公司 | 冻干脂质纳米颗粒的方法 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4208196A1 (en) | 2020-09-03 | 2023-07-12 | Flagship Pioneering Innovations VI, LLC | Immunogenic compositions and uses thereof |
| WO2022104131A1 (en) | 2020-11-13 | 2022-05-19 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| EP4008785A1 (en) | 2020-12-03 | 2022-06-08 | Justus-Liebig-Universität Gießen | Circular nucleic acids and uses thereof for interfering with genome expression and proliferation of coronaviruses |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| WO2022137128A2 (en) | 2020-12-23 | 2022-06-30 | Glaxosmithkline Biologicals Sa | Self-amplifying messenger rna |
| EP4032546A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Therapeutic viral vaccine |
| CN117098558A (zh) * | 2021-02-09 | 2023-11-21 | 塞瑞纳治疗公司 | 聚噁唑啉-脂质缀合物及包含其的脂质纳米颗粒和药物组合物 |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| WO2022204370A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency |
| WO2022204380A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
| US20240226025A1 (en) | 2021-03-24 | 2024-07-11 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
| WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
| WO2022204371A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
| MX2023011400A (es) | 2021-03-26 | 2023-10-09 | Glaxosmithkline Biologicals Sa | Composiciones inmunogenicas. |
| US20240358852A1 (en) | 2021-04-20 | 2024-10-31 | Anjarium Biosciences Ag | Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof |
| WO2022232289A1 (en) | 2021-04-27 | 2022-11-03 | Generation Bio Co. | Non-viral dna vectors expressing therapeutic antibodies and uses thereof |
| EP4329884A1 (en) | 2021-04-27 | 2024-03-06 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
| CN113230394B (zh) * | 2021-04-30 | 2024-04-30 | 广州源博医药科技有限公司 | 一种用于牛病毒性腹泻的rna疫苗及其构建方法 |
| EP4346894A1 (en) | 2021-05-24 | 2024-04-10 | GlaxoSmithKline Biologicals S.A. | Adjuvants |
| US20240272143A1 (en) | 2021-06-09 | 2024-08-15 | Glaxosmithkline Biologicals Sa | Release assay for determining potency of self-amplifying rna drug product and methods for using |
| US20240384277A1 (en) | 2021-06-15 | 2024-11-21 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
| US20240376445A1 (en) | 2021-06-22 | 2024-11-14 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| WO2023283359A2 (en) | 2021-07-07 | 2023-01-12 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
| US20240342206A1 (en) | 2021-07-30 | 2024-10-17 | CureVac SE | mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| EP4387597A1 (en) | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| CA3229889A1 (en) | 2021-09-03 | 2023-03-09 | Glaxosmithkline Biologicals Sa | Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids |
| WO2023056044A1 (en) | 2021-10-01 | 2023-04-06 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease |
| AU2022369342A1 (en) | 2021-10-18 | 2024-03-14 | BioNTech SE | Modified replicable rna and related compositions and their use |
| WO2023066874A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
| CN118541346A (zh) | 2021-11-08 | 2024-08-23 | 奥纳治疗公司 | 用于递送环状多核苷酸的脂质纳米颗粒组合物 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| JP2025504404A (ja) | 2022-01-14 | 2025-02-12 | アンジャリウム バイオサイエンシズ エージー | Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法 |
| EP4466027A1 (en) | 2022-01-17 | 2024-11-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of inducing cell death of a population of solid tumor cells |
| WO2023144193A1 (en) | 2022-01-25 | 2023-08-03 | CureVac SE | Mrnas for treatment of hereditary tyrosinemia type i |
| WO2023152365A1 (en) | 2022-02-14 | 2023-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of the 15-lipoxygenase for the treatment of lymphedema |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| AU2023235112A1 (en) | 2022-03-14 | 2024-10-17 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
| WO2023183909A2 (en) | 2022-03-25 | 2023-09-28 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
| WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
| AU2023283348A1 (en) | 2022-06-07 | 2025-01-09 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
| WO2023242817A2 (en) | 2022-06-18 | 2023-12-21 | Glaxosmithkline Biologicals Sa | Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
| AU2023316015A1 (en) | 2022-07-25 | 2025-02-13 | Centre Hospitalier Universitaire De Toulouse | Use of apelin for the treatment of lymphedema |
| MA71619A (fr) | 2022-07-26 | 2025-05-30 | Modernatx, Inc. | Polynucléotides modifiés pour la régulation temporelle de l'expression |
| US20260055426A1 (en) | 2022-08-19 | 2026-02-26 | Generation Bio Co. | CLEAVABLE CLOSED-ENDED DNA (ceDNA) AND METHODS OF USE THEREOF |
| WO2024044147A1 (en) | 2022-08-23 | 2024-02-29 | Modernatx, Inc. | Methods for purification of ionizable lipids |
| WO2024047247A1 (en) | 2022-09-02 | 2024-03-07 | Institut National de la Santé et de la Recherche Médicale | Base editing approaches for the treatment of amyotrophic lateral sclerosis |
| CA3267295A1 (en) | 2022-09-15 | 2024-03-21 | TRON – TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH-Aysegul YILDIZ | SYSTEMS AND COMPOSITIONS CONTAINING TRANS-AMPLIFYING RNA VECTORS WITH MIARN |
| CA3267272A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | FLU VIRUS VACCINES |
| WO2024085149A1 (ja) | 2022-10-18 | 2024-04-25 | 第一三共株式会社 | テイラー反応装置及びカプセル粒子の製造方法 |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| TW202425959A (zh) | 2022-11-08 | 2024-07-01 | 美商歐納醫療公司 | 遞送多核苷酸的脂質及奈米顆粒組合物 |
| WO2024102677A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Circular rna compositions |
| IL320873A (en) | 2022-12-01 | 2025-07-01 | Generation Bio Co | Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions containing them |
| JP2025540076A (ja) | 2022-12-01 | 2025-12-11 | ジェネレーション バイオ カンパニー | 核酸、イオン化可能な脂質、ステロール、脂質アンカーポリマー、及びヘルパー脂質を含む脂質ナノ粒子、それらの使用 |
| WO2024119103A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
| JP2025541726A (ja) | 2022-12-01 | 2025-12-23 | ジェネレーション バイオ カンパニー | 細胞標的化のためのステルス脂質ナノ粒子組成物 |
| WO2024121378A1 (en) | 2022-12-09 | 2024-06-13 | Institut National de la Santé et de la Recherche Médicale | Novel human antiviral genes related to the eleos and lamassu prokaryotic systems |
| WO2024133160A1 (en) | 2022-12-19 | 2024-06-27 | Glaxosmithkline Biologicals Sa | Hepatitis b compositions |
| WO2024149697A1 (en) | 2023-01-09 | 2024-07-18 | Institut National de la Santé et de la Recherche Médicale | Use of the recombinant fibrinogen-like domain of angiopoietin-like 4 for treating adverse post-ischemic cardiac remodeling in a patient who experienced a myocardial infarction |
| WO2024153636A1 (en) | 2023-01-17 | 2024-07-25 | Institut National de la Santé et de la Recherche Médicale | Vasorin as a biomarker and biotarget in nephrology |
| WO2024156835A1 (en) | 2023-01-27 | 2024-08-02 | Institut National de la Santé et de la Recherche Médicale | Use of amphiregulin (areg) in methods of treating vascular hyperpermeability |
| EP4658239A1 (en) | 2023-02-03 | 2025-12-10 | GlaxoSmithKline Biologicals S.A. | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| WO2024197033A1 (en) | 2023-03-21 | 2024-09-26 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of heart failure |
| JP2026511495A (ja) | 2023-03-23 | 2026-04-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ウイルス複製のモジュレートのための、ｇａｓ７の発現及び／又は活性のモジュレート |
| WO2024205657A2 (en) | 2023-03-29 | 2024-10-03 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| EP4701657A1 (en) | 2023-04-27 | 2026-03-04 | GlaxoSmithKline Biologicals S.A. | Influenza virus vaccines |
| WO2024223728A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| AU2024265267A1 (en) | 2023-05-03 | 2025-11-20 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| AU2024269222A1 (en) | 2023-05-05 | 2025-10-09 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2024243438A2 (en) | 2023-05-23 | 2024-11-28 | Omega Therapeutics, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| CN121263216A (zh) | 2023-06-06 | 2026-01-02 | 赢创运营有限公司 | 由胶原样蛋白(clp)制备的水凝胶贴剂 |
| CN121532514A (zh) | 2023-07-07 | 2026-02-13 | 上海环码生物医药有限公司 | 用于季节性流感的环状rna疫苗及使用方法 |
| WO2025019352A2 (en) * | 2023-07-14 | 2025-01-23 | Modernatx, Inc. | Mers-cov mrna vaccines |
| WO2025040709A1 (en) | 2023-08-24 | 2025-02-27 | BioNTech SE | Systems and compositions comprising highly active trans-amplifying replicases |
| WO2025045142A1 (en) | 2023-08-29 | 2025-03-06 | Shanghai Circode Biomed Co., Ltd. | Circular rna encoding vegf polypeptides, formulations, and methods of uses |
| WO2025049690A1 (en) | 2023-08-29 | 2025-03-06 | Orna Therapeutics, Inc. | Circular polyethylene glycol lipids |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
| WO2025052180A2 (en) | 2023-09-07 | 2025-03-13 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2025051381A1 (en) | 2023-09-08 | 2025-03-13 | BioNTech SE | Methods and compositions for localized expression of administered rna |
| WO2025072482A1 (en) | 2023-09-27 | 2025-04-03 | Modernatx, Inc. | Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof |
| WO2025083211A1 (en) | 2023-10-20 | 2025-04-24 | Institut National de la Santé et de la Recherche Médicale | Use of factor h for the treatment of dementia |
| WO2025101501A1 (en) | 2023-11-07 | 2025-05-15 | Orna Therapeutics, Inc. | Circular rna compositions |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
| WO2025215072A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Class i lanthipeptides with anti-viral function |
| WO2025229572A1 (en) | 2024-05-01 | 2025-11-06 | Glaxosmithkline Biologicals Sa | Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines |
| WO2025248096A1 (en) | 2024-05-31 | 2025-12-04 | Institut National de la Santé et de la Recherche Médicale | Antimicrobial peptides having liquid-liquid phase separation activities |
| WO2025255199A1 (en) | 2024-06-05 | 2025-12-11 | Modernatx, Inc. | Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026064512A1 (en) | 2024-09-18 | 2026-03-26 | Generation Bio Co. | Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same |
| WO2026085495A1 (en) | 2024-10-18 | 2026-04-23 | Generation Bio Co. | Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor |
| WO2026093547A1 (en) | 2024-10-31 | 2026-05-07 | Institut National de la Santé et de la Recherche Médicale | Methods and vaccine compositions for the treatment of cancer |
Family Cites Families (258)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US4853228A (en) * | 1987-07-28 | 1989-08-01 | Micro-Pak, Inc. | Method of manufacturing unilamellar lipid vesicles |
| US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
| EP0737750B1 (en) | 1989-03-21 | 2003-05-14 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| FR2676072B1 (fr) | 1991-05-03 | 1994-11-18 | Transgene Sa | Vecteur de delivrance d'arn. |
| US5693535A (en) | 1992-05-14 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | HIV targeted ribozymes |
| US5750390A (en) | 1992-08-26 | 1998-05-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of diseases caused by expression of the bcl-2 gene |
| WO1993024640A2 (en) | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
| EP1251170A3 (en) | 1992-07-17 | 2002-10-30 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of NF-kappaB dependent animal diseases |
| US5474914A (en) | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
| US20020102273A1 (en) | 1995-08-08 | 2002-08-01 | Robert B. Grieve | Use of alphavirus expression vectors to produce parasite anitgens |
| EP0702516A4 (en) | 1993-06-01 | 1998-04-22 | Life Technologies Inc | GENETIC IMMUNIZATION WITH CATIONIC LIPIDS |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| JPH08511956A (ja) | 1994-04-07 | 1996-12-17 | アクゾ・ノベル・エヌ・ベー | Ｒｎａを含む凍結乾燥組成物 |
| US5993850A (en) * | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5965434A (en) | 1994-12-29 | 1999-10-12 | Wolff; Jon A. | Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| CA2230033C (en) * | 1995-09-27 | 2010-01-26 | Peter L. Collins | Production of infectious respiratory syncytial virus from cloned nucleotide sequences |
| CA2244110A1 (en) | 1996-02-12 | 1997-08-14 | Cobra Therapeutics Limited | Novel methods of vaccination and vaccines thereof comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope |
| DE19605548A1 (de) | 1996-02-15 | 1997-09-04 | Boehringer Ingelheim Int | Zusammensetzung für die Transfektion höherer eukaryotischer Zellen |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| ATE273320T1 (de) | 1996-04-11 | 2004-08-15 | Univ British Columbia | Fusogene liposomen |
| WO1998000110A1 (en) | 1996-07-03 | 1998-01-08 | University Of Pittsburgh | Emulsion formulations for hydrophilic active agents |
| ATE395904T1 (de) | 1996-09-13 | 2008-06-15 | Lipoxen Technologies Ltd | Liposome |
| US7384923B2 (en) | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
| US6395302B1 (en) | 1996-11-19 | 2002-05-28 | Octoplus B.V. | Method for the preparation of microspheres which contain colloidal systems |
| WO1998051278A2 (en) | 1997-05-14 | 1998-11-19 | Inex Pharmaceuticals Corporation | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US6048546A (en) | 1997-07-31 | 2000-04-11 | Sandia Corporation | Immobilized lipid-bilayer materials |
| US6060308A (en) | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
| WO1999028487A1 (en) | 1997-11-28 | 1999-06-10 | The Crown In The Right Of The Queensland Department Of Health | Flavivirus expression and delivery system |
| US6009406A (en) | 1997-12-05 | 1999-12-28 | Square D Company | Methodology and computer-based tools for re-engineering a custom-engineered product line |
| GB9726555D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
| US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
| EP2311436A1 (en) | 1998-04-27 | 2011-04-20 | Altus Pharmaceuticals Inc. | Stabilized protein crystals, formulations containing them and methods of making them |
| WO2000000616A2 (en) | 1998-06-29 | 2000-01-06 | U.S. Medical Research Institute Of Infectious Diseases | Marburg virus vaccines |
| WO2000003683A2 (en) | 1998-07-20 | 2000-01-27 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| EP1980617A1 (en) | 1998-12-31 | 2008-10-15 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
| DE69943068D1 (de) | 1999-09-09 | 2011-02-03 | Curevac Gmbh | Transfer von mRNA unter Verwendung von polykationischen Verbindungen |
| CN1411512A (zh) | 1999-10-20 | 2003-04-16 | 约翰霍普金斯大学医学院 | 嵌合的免疫原性组合物及其编码核酸 |
| US8541008B2 (en) * | 1999-11-19 | 2013-09-24 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against candidiasis |
| US20030212022A1 (en) | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
| WO2001079253A1 (en) | 2000-04-18 | 2001-10-25 | Human Genome Sciences, Inc. | Extracellular matrix polynucleotides, polypeptides, and antibodies |
| CN1254234C (zh) * | 2000-06-09 | 2006-05-03 | 莱古伦公司 | 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中 |
| CA2414884A1 (en) | 2000-07-03 | 2002-01-10 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
| WO2002009645A2 (en) | 2000-08-01 | 2002-02-07 | The Johns Hopkins University | Intercellular transport protein linked to an antigen as a molecular vaccine |
| US20040142474A1 (en) | 2000-09-14 | 2004-07-22 | Expression Genetics, Inc. | Novel cationic lipopolymer as a biocompatible gene delivery agent |
| MXPA03002640A (es) | 2000-09-28 | 2003-06-19 | Chiron Corp | Microparticulas para la distribucion de acidos nucleicos heterologos. |
| ATE439372T1 (de) | 2000-10-27 | 2009-08-15 | Novartis Vaccines & Diagnostic | Nukleinsäuren und proteine von gruppen a und b- streptokokken |
| WO2002079239A2 (en) | 2001-01-31 | 2002-10-10 | U.S. Army Medical Research Institute Of Infectious Diseases | Chimeric filovirus glycoprotein |
| WO2002061113A2 (en) | 2001-02-01 | 2002-08-08 | The Johns Hopkins University | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
| AU2002306709A1 (en) | 2001-03-14 | 2002-09-24 | Replicon Technologies, Inc. | Oncolytic rna replicons |
| AU2002306736A1 (en) | 2001-03-16 | 2002-10-03 | Johns Hopkins University | A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same |
| AU2002256398A2 (en) | 2001-04-30 | 2002-11-11 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
| US20030077251A1 (en) | 2001-05-23 | 2003-04-24 | Nicolas Escriou | Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins |
| EP1903054A3 (de) | 2001-06-05 | 2008-07-23 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
| WO2003018054A1 (en) | 2001-08-31 | 2003-03-06 | Chiron Srl. | Helicobacter pylori vaccination |
| US7045335B2 (en) * | 2001-09-06 | 2006-05-16 | Alphavax, Inc. | Alphavirus replicon vector systems |
| WO2003068190A1 (en) | 2002-02-13 | 2003-08-21 | Northeastern University | Intracellular delivery of therapeutic agents |
| DE10207177A1 (de) | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| EP1519745B1 (en) | 2002-07-05 | 2006-12-20 | Lipoxen Technologies Limited | Method to enhance an immune response of nucleic acid vaccination |
| ES2242462B1 (es) | 2002-07-18 | 2007-01-01 | Marti Industria Metalurgica, S.L | Pulverizador giratorio seleccionable. |
| WO2004018506A2 (en) * | 2002-08-22 | 2004-03-04 | Cytos Biotechnology Ag | Inducible alphaviral/orip based gene expression system |
| JP2005538186A (ja) * | 2002-09-13 | 2005-12-15 | レプリコール インコーポレーティッド | 非配列相補性の抗ウイルス性オリゴヌクレオチド |
| EP1585812B1 (en) | 2002-12-13 | 2017-01-18 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
| AU2003301148A1 (en) | 2002-12-23 | 2004-07-22 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| US8338583B2 (en) | 2003-02-04 | 2012-12-25 | Bar-Ilan University | Snornai-small nucleolar RNA degradation by RNA interference in trypanosomatids |
| US20040228842A1 (en) | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
| KR101518309B1 (ko) | 2003-03-20 | 2015-05-08 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
| US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
| US20070042979A1 (en) | 2003-05-30 | 2007-02-22 | Junichi Yano | Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite |
| CA2526106A1 (en) | 2003-06-26 | 2005-01-13 | Chiron Corporation | Immunogenic compositions for chlamydia trachomatis |
| EP1651666B1 (en) | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
| US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
| SG190613A1 (en) | 2003-07-16 | 2013-06-28 | Protiva Biotherapeutics Inc | Lipid encapsulated interfering rna |
| JP4875490B2 (ja) | 2003-07-31 | 2012-02-15 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物 |
| EP1512393A1 (de) * | 2003-09-08 | 2005-03-09 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Verfahren zur Herstellung von homogenen Liposomen und Lipoplexen |
| CN1882693B (zh) | 2003-09-15 | 2012-08-15 | 普洛体维生物治疗公司 | 聚乙二醇修饰的脂质化合物及其应用 |
| US20050208020A1 (en) | 2003-11-12 | 2005-09-22 | Doolan Denise L | Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines |
| US20050202075A1 (en) | 2004-03-12 | 2005-09-15 | Pardridge William M. | Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers |
| US7303881B2 (en) | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| US20060024670A1 (en) | 2004-05-18 | 2006-02-02 | Luke Catherine J | Influenza virus vaccine composition and methods of use |
| ES2321212T3 (es) | 2004-05-18 | 2009-06-03 | Alphavax, Inc. | Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion. |
| ES2647491T3 (es) | 2004-05-21 | 2017-12-21 | Novartis Vaccines And Diagnostics, Inc. | Vectores del alfavirus para las vacunas del virus de la gripe |
| GB0411428D0 (en) | 2004-05-21 | 2004-06-23 | Got A Gene Ab | Vectors |
| US20080268429A1 (en) * | 2004-06-02 | 2008-10-30 | Sourcepharm, Inc. | Rna - Containing Microvesicles and Methods Therefor |
| WO2005120152A2 (en) | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| ATE536418T1 (de) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | Lipidverkapselte interferenz-rna |
| US7862829B2 (en) | 2004-07-09 | 2011-01-04 | University Of North Carolina At Chapel Hill | Viral adjuvants |
| WO2006007712A1 (en) * | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| WO2006038129A2 (en) | 2004-10-01 | 2006-04-13 | Novartis Vaccines And Diagnostics Srl | Hepatitis c virus replication system |
| CA2587337A1 (en) | 2004-11-19 | 2006-05-26 | Novosom Ag | Improvements in or relating to pharmaceutical compositions for local administration |
| GB2421025A (en) | 2004-12-09 | 2006-06-14 | Oxxon Therapeutics Ltd | HSV vaccination vectors |
| WO2007086883A2 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| JP2008530245A (ja) | 2005-02-18 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 尿路病原性菌株由来の抗原 |
| SI2351772T1 (sl) | 2005-02-18 | 2016-11-30 | Glaxosmithkline Biologicals Sa | Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso |
| WO2006092607A1 (en) | 2005-03-02 | 2006-09-08 | The Secretary Of State For Defence | Pharmaceutical composition |
| GB0504436D0 (en) | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
| CA2602665A1 (en) | 2005-03-30 | 2006-10-19 | Novartis Vaccines And Diagnostics, Inc. | Haemophilus influenzae type b |
| US7618393B2 (en) | 2005-05-03 | 2009-11-17 | Pharmajet, Inc. | Needle-less injector and method of fluid delivery |
| US8133973B2 (en) | 2005-05-12 | 2012-03-13 | Novartis Vaccines And Diagnostics, S.R.L. | Immunogenic compositions for Chlamydia trachomatis |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| WO2007014754A1 (en) * | 2005-08-02 | 2007-02-08 | I.D.M. Immuno-Designed Molecules | Process for the preparation of liposomal formulations |
| US7951384B2 (en) | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| HUE043492T2 (hu) | 2005-08-23 | 2019-08-28 | Univ Pennsylvania | Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására |
| EP1764089A1 (en) | 2005-09-15 | 2007-03-21 | Novosom AG | Serum stable liposomes comprising amphoter II lipid mixtures |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| NZ567270A (en) | 2005-09-29 | 2011-06-30 | Elan Pharm Inc | Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| CA2626253A1 (en) | 2005-10-18 | 2007-04-26 | Novartis Vaccines And Diagnostics, Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
| JP2007112768A (ja) | 2005-10-24 | 2007-05-10 | Kyoto Univ | 肝指向性リポソーム組成物 |
| US7776336B2 (en) | 2005-10-25 | 2010-08-17 | Novartis Vaccines And Diagnostics Srl | Compositions comprising Yersinia pestis antigens |
| AU2006335256B2 (en) | 2005-11-22 | 2012-10-18 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
| WO2008051245A2 (en) | 2005-12-02 | 2008-05-02 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| EP2004141A2 (en) | 2006-03-17 | 2008-12-24 | Novosom AG | An efficient method for loading amphoteric liposomes with nucleic acid active substances |
| WO2007120863A2 (en) | 2006-04-14 | 2007-10-25 | Epicentre Technologies | Kits and methods for generating 5' capped rna |
| CA2654563A1 (en) | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| CA2657217A1 (en) | 2006-06-21 | 2007-12-27 | The Scripps Research Institute | Dna composition against tumor stromal antigen fap and methods of use thereof |
| WO2008016473A2 (en) | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
| EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
| ES2517869T3 (es) | 2006-09-12 | 2014-11-04 | Alphavax, Inc. | Partículas de replicones de alfavirus emparejadas con antígenos proteicos como adyuvantes inmunológicos |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| US20080171078A1 (en) | 2007-01-12 | 2008-07-17 | Mark Gray | Uniformly sized liposomes |
| JP2010519203A (ja) * | 2007-02-16 | 2010-06-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 生物活性分子の活性を強化するための組成物及び方法 |
| US20100196492A1 (en) | 2007-03-08 | 2010-08-05 | Green Jordan J | Electrostatic coating of particles for drug delivery |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| JP5350360B2 (ja) * | 2007-03-29 | 2013-11-27 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | エボラ由来の遺伝子の発現を阻害するための組成物および方法 |
| US8748591B2 (en) | 2007-04-17 | 2014-06-10 | The Board Of Regents Of The University Of Texas System | Chimeric sindbis-western equine encephalitis virus and uses thereof |
| LT2494993T (lt) | 2007-05-04 | 2018-12-27 | Marina Biotech, Inc. | Aminorūgščių lipidai ir jų panaudojimas |
| CA2688061A1 (en) | 2007-05-23 | 2008-12-04 | Mannkind Corporation | Multicistronic vectors and methods for their design |
| DE102007029471A1 (de) | 2007-06-20 | 2008-12-24 | Novosom Ag | Neue fakultativ kationische Sterole |
| DK2183368T3 (da) | 2007-06-21 | 2016-09-05 | Alphavax Inc | Promoterfrie kassetter til ekspression af alphavirusstrukturproteiner |
| US8202518B2 (en) | 2007-07-04 | 2012-06-19 | Ribovax Biotechnologies S.A. | Antibodies against human cytomegalovirus (HCMV) |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| US20110177155A1 (en) | 2007-08-21 | 2011-07-21 | Immune Disease Institute, Inc. | Methods of delivery of agents to leukocytes and endothelial cells |
| GB0717187D0 (en) | 2007-09-04 | 2007-10-17 | Novartis Ag | Compositions comprising yersinia pestis antigens |
| EP2205751A2 (en) | 2007-09-26 | 2010-07-14 | Vanderbilt University | Vaccine for rsv and mpv |
| EP2042193A1 (en) | 2007-09-28 | 2009-04-01 | Biomay AG | RNA Vaccines |
| US8470560B2 (en) * | 2007-10-03 | 2013-06-25 | The United States Of America As Represented By The Secretary Of The Army | CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines |
| WO2009079185A2 (en) | 2007-11-26 | 2009-06-25 | Novartis Vaccines And Diagnostics, Inc. | Methods of generating alphavirus particles |
| EP2067749A1 (en) | 2007-11-29 | 2009-06-10 | Total Petrochemicals France | Process for purification of an aqueous phase containing polyaromatics |
| WO2009074861A2 (en) | 2007-12-10 | 2009-06-18 | Powderject Research Limited | Improved vaccine |
| JP5749494B2 (ja) * | 2008-01-02 | 2015-07-15 | テクミラ ファーマシューティカルズ コーポレイション | 核酸の送達のための改善された組成物および方法 |
| WO2009111088A2 (en) * | 2008-01-02 | 2009-09-11 | The Johns Hopkins University | Antitumor immunization by liposomal delivery of vaccine to the spleen |
| ITMI20081249A1 (it) | 2008-07-09 | 2010-01-09 | Novartis Vaccines & Diagnostic | Immunogeni di escherichia coli con solubilità migliorata. |
| US20110110857A1 (en) | 2008-03-06 | 2011-05-12 | Roberto Petracca | Mutant forms of chlamydia htra |
| NZ588583A (en) | 2008-04-15 | 2012-08-31 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| WO2009132131A1 (en) | 2008-04-22 | 2009-10-29 | Alnylam Pharmaceuticals, Inc. | Amino lipid based improved lipid formulation |
| WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
| US20100040650A1 (en) | 2008-05-30 | 2010-02-18 | Crowe Jr James E | Virus-Like paramyxovirus particles and vaccines |
| EP2130912A1 (en) * | 2008-06-04 | 2009-12-09 | Institut für Viruskrankeiten und Immunprophylaxe | Pestivirus replicons providing an RNA-based viral vector system |
| WO2009156155A1 (en) | 2008-06-25 | 2009-12-30 | Probiogen Ag | Cell line for propagation of highly attenuated alphaviruses |
| JP5712126B2 (ja) | 2008-06-25 | 2015-05-07 | ノバルティス アーゲー | 遅延型追加刺激免疫処置に対する迅速な応答 |
| JP2010025644A (ja) | 2008-07-16 | 2010-02-04 | Kochi Univ Of Technology | 硝酸イオンの呈色試薬並びにこれを用いた硝酸イオンの検出及び定量方法 |
| PT3009449T (pt) | 2008-07-16 | 2018-09-28 | Inst Res Biomedicine | Anticorpos neutralizantes de citomegalovírus humano e utilização destes |
| KR101407216B1 (ko) | 2008-07-16 | 2014-06-16 | 인스티튜트 포 리서치 인 바이오메드슨 | 인간 사이토메갈바이러스 중화 항체 및 이의 용도 |
| EP2328614A1 (en) | 2008-08-06 | 2011-06-08 | Novartis AG | Microparticles for use in immunogenic compositions |
| CL2008002322A1 (es) | 2008-08-07 | 2009-06-05 | Univ Concepcion | Formulacion farmaceutica veterinaria que comprende un sistema vectorial viral constituido por una particula recombinante de arn que codifica una cu/zn superoxido dismutasa de la bacteria patogena de bovinos brucella abortus, y al menos un alfavirus arn perteneciente a la familia del virus semliki forest (sfv), util como vacuna. |
| CN102123698B (zh) | 2008-08-13 | 2016-06-22 | 加利福尼亚技术学院 | 载体纳米颗粒和相关的组合物、方法和系统 |
| US20110177122A1 (en) | 2008-09-26 | 2011-07-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | Dna prime/activated vaccine boost immunization to influenza virus |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| JP5777519B2 (ja) | 2008-10-09 | 2015-09-09 | テクミラ ファーマシューティカルズ コーポレイション | 改良されたアミノ脂質および核酸の送達方法 |
| MX2011004859A (es) | 2008-11-07 | 2011-08-03 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
| EP4241767B1 (en) | 2008-11-10 | 2024-10-23 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| WO2010059689A2 (en) | 2008-11-18 | 2010-05-27 | Ligocyte Pharmaceuticals, Inc. | Rsv f vlps and methods of manufacture and use thereof |
| US20120101148A1 (en) * | 2009-01-29 | 2012-04-26 | Alnylam Pharmaceuticals, Inc. | lipid formulation |
| NZ612315A (en) | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| CA2760706C (en) | 2009-05-05 | 2019-08-06 | Alnylam Pharmaceuticals, Inc. | Methods of delivering oligonucleotides to immune cells |
| TR201811076T4 (tr) | 2009-06-10 | 2018-08-27 | Arbutus Biopharma Corp | Geliştirilmiş lipit formulasyonu. |
| US8283333B2 (en) | 2009-07-01 | 2012-10-09 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
| WO2011001780A1 (ja) | 2009-07-02 | 2011-01-06 | コニカミノルタホールディングス株式会社 | 特定分散剤を含有する外水相を利用する二段階乳化法によるリポソームの製造方法、ならびに当該リポソームの製造方法を用いるリポソーム分散液またはその乾燥粉末の製造方法およびそれにより製造されるリポソーム分散液またはその乾燥粉末 |
| EP2451475A2 (en) * | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| TW201116294A (en) | 2009-07-15 | 2011-05-16 | Novartis Ag | RSV F protein compositions and methods for making same |
| EP2453914B1 (en) | 2009-07-16 | 2018-09-05 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope -based anti-infective vaccines |
| EP3165234B1 (de) | 2009-07-31 | 2019-04-03 | ethris GmbH | Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression |
| AU2010290896B2 (en) | 2009-09-02 | 2014-07-03 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions including TLR activity modulators |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| US20110070260A1 (en) | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
| CN107028886A (zh) | 2009-11-04 | 2017-08-11 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
| US20110112353A1 (en) | 2009-11-09 | 2011-05-12 | Circulite, Inc. | Bifurcated outflow cannulae |
| PL3338765T3 (pl) | 2009-12-01 | 2019-06-28 | Translate Bio, Inc. | Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych |
| KR101878502B1 (ko) | 2009-12-07 | 2018-07-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 세포 리프로그래밍을 위한 정제된 변형 ｒｎａ를 포함하는 ｒｎａ 제제 |
| WO2011071860A2 (en) | 2009-12-07 | 2011-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions for nucleic acid delivery |
| EP3494963A1 (en) | 2009-12-18 | 2019-06-12 | The University of British Columbia | Methods and compositions for delivery of nucleic acids |
| AU2010334911A1 (en) | 2009-12-23 | 2012-07-12 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| CA2787598A1 (en) | 2010-01-24 | 2012-06-21 | Novartis Ag | Irradiated biodegradable polymer microparticles |
| CA2792679C (en) | 2010-03-09 | 2019-11-12 | Mucosal Vaccine Thechnologies Llc | A novel mucosal vaccination approach for herpes simplex virus type-2 |
| JP2013529894A (ja) | 2010-04-07 | 2013-07-25 | ノバルティス アーゲー | パルボウイルスｂ１９のウイルス様粒子を生成するための方法 |
| AU2011276234B2 (en) | 2010-07-06 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Liposomes with lipids having an advantageous pKa- value for RNA delivery |
| US11291635B2 (en) | 2010-07-06 | 2022-04-05 | Glaxosmithkline Biological Sa | Virion-like delivery particles for self-replicating RNA molecules |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| EP3449910A1 (en) | 2010-07-06 | 2019-03-06 | GlaxoSmithKline Biologicals S.A. | Cationic oil-in-water emulsions |
| CA2804501C (en) | 2010-07-06 | 2021-01-26 | Novartis Ag | Noro virus derived immunogenic compositions and methods |
| SI2591114T1 (sl) | 2010-07-06 | 2016-10-28 | Glaxosmithkline Biologicals S.A. | Imunizacija velikih sesalcev z majhnimi odmerki RNA |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| US8898852B2 (en) | 2010-08-04 | 2014-12-02 | Honeywell International Inc. | Air burst to clear detection window |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012031043A1 (en) | 2010-08-31 | 2012-03-08 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| TR201908635T4 (tr) | 2010-08-31 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Protein kodlayıcı rna?nın lipozomal verilmesine uygun lipitler. |
| BR112013004879A2 (pt) | 2010-08-31 | 2018-04-24 | Novartis Ag | lipossomas pequenos para entrega de rna que codifica imunogénio |
| US20130164289A1 (en) | 2010-09-09 | 2013-06-27 | Virginia Commonwealth University | Human cytomegalovirus vaccine |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| EP3520813B1 (en) | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| AU2011323844B2 (en) | 2010-10-25 | 2016-09-08 | Stepan Company | Quaternized fatty amines, amidoamines, and their derivatives from natural oil metathesis |
| EP4144368B1 (en) | 2011-01-26 | 2025-02-26 | GlaxoSmithKline Biologicals S.A. | Rsv immunization regimen |
| EA033467B1 (ru) | 2011-01-31 | 2019-10-31 | Univ Pennsylvania | Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| CN103842374A (zh) | 2011-05-13 | 2014-06-04 | 诺华股份有限公司 | 融合前的rsv f抗原 |
| CN103687957A (zh) | 2011-05-17 | 2014-03-26 | 现代治疗公司 | 工程化核酸及其用于非人类脊椎动物的方法 |
| DK3336082T3 (da) | 2011-06-08 | 2020-04-27 | Translate Bio Inc | Spaltelige lipider |
| EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| EP4014966A1 (en) | 2011-07-06 | 2022-06-22 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| AU2012280901B2 (en) | 2011-07-06 | 2016-11-10 | Glaxosmithkline Biologicals S.A. | Oil-in-water emulsions that contain nucleic acids |
| RU2649133C2 (ru) | 2011-07-06 | 2018-03-29 | Новартис Аг | Катионные эмульсии масло-в-воде |
| CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| SG11201400250UA (en) | 2011-08-31 | 2014-03-28 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| WO2013039861A2 (en) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| US20140271829A1 (en) | 2011-10-11 | 2014-09-18 | Anders Lilja | Recombinant self-replicating polycistronic rna molecules |
| EP2766385A2 (en) | 2011-10-12 | 2014-08-20 | Novartis AG | Cmv antigens and uses thereof |
| WO2013130161A1 (en) | 2011-12-14 | 2013-09-06 | modeRNA Therapeutics | Methods of responding to a biothreat |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| CN104968354A (zh) | 2011-12-21 | 2015-10-07 | 现代治疗公司 | 增加器官或器官外植体的活力或寿命的方法 |
| CN108949772A (zh) | 2012-04-02 | 2018-12-07 | 现代泰克斯公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| WO2014108515A1 (en) | 2013-01-10 | 2014-07-17 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof |
| US9504747B2 (en) | 2013-03-08 | 2016-11-29 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US20160032316A1 (en) | 2013-03-14 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| PT3083556T (pt) | 2013-12-19 | 2020-03-05 | Novartis Ag | Lípidos e composições lipídicas para a entrega de agentes ativos |
| US9686692B2 (en) | 2014-03-20 | 2017-06-20 | Microsoft Technology Licesning, LLC | Wi-Fi tile transfer |
| WO2015144732A2 (en) * | 2014-03-25 | 2015-10-01 | Yale University | Uses of parasite macrophage migration inhibitory factors |
| IL316479A (en) | 2014-06-25 | 2024-12-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle compositions for nucleic acid delivery |
| HUE067372T2 (hu) | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| RS63030B1 (sr) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
| RS63986B1 (sr) | 2015-10-28 | 2023-03-31 | Acuitas Therapeutics Inc | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| AU2017345766A1 (en) | 2016-10-21 | 2019-05-16 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| MX2019005470A (es) | 2016-11-10 | 2019-11-21 | Translate Bio Inc | Formulación de nanopartículas lipídicas basadas en ice mejorada para el suministro de arnm. |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| EP3883592A1 (en) | 2018-11-21 | 2021-09-29 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr |
| EP4021407A1 (en) | 2019-08-30 | 2022-07-06 | GlaxoSmithKline Biologicals S.A. | Jet mixing lipid nanoparticle manufacturing process |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| WO2022150717A1 (en) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
-
2011
- 2011-08-31 WO PCT/US2011/050095 patent/WO2012031043A1/en not_active Ceased
- 2011-08-31 HU HUE11758014A patent/HUE058361T2/hu unknown
- 2011-08-31 HR HRP20220835TT patent/HRP20220835T8/hr unknown
- 2011-08-31 EP EP23179901.6A patent/EP4226941B1/en active Active
- 2011-08-31 PT PT231799016T patent/PT4226941T/pt unknown
- 2011-08-31 EP EP22174931.0A patent/EP4066856B1/en active Active
- 2011-08-31 FI FIEP22174932.8T patent/FI4066857T3/fi active
- 2011-08-31 EP EP11758014.2A patent/EP2611461B1/en active Active
- 2011-08-31 ES ES11758014T patent/ES2913791T3/es active Active
- 2011-08-31 PT PT212078596T patent/PT3970742T/pt unknown
- 2011-08-31 EP EP22192507.6A patent/EP4119155A1/en not_active Withdrawn
- 2011-08-31 HR HRP20220695TT patent/HRP20220695T1/hr unknown
- 2011-08-31 ES ES22174932T patent/ES2938327T3/es active Active
- 2011-08-31 SM SM20220497T patent/SMT202200497T1/it unknown
- 2011-08-31 ES ES22174931T patent/ES2935009T3/es active Active
- 2011-08-31 SI SI201132082T patent/SI4066857T1/sl unknown
- 2011-08-31 PT PT221749328T patent/PT4066857T/pt unknown
- 2011-08-31 RS RS20220594A patent/RS63367B1/sr unknown
- 2011-08-31 HR HRP20230226TT patent/HRP20230226T1/hr unknown
- 2011-08-31 HU HUE22174931A patent/HUE060524T2/hu unknown
- 2011-08-31 EP EP23179897.6A patent/EP4226940A1/en active Pending
- 2011-08-31 EP EP22192506.8A patent/EP4147718A1/en not_active Withdrawn
- 2011-08-31 PL PL21207859.6T patent/PL3970742T3/pl unknown
- 2011-08-31 DK DK21207859.6T patent/DK3970742T3/da active
- 2011-08-31 PL PL22174932.8T patent/PL4066857T3/pl unknown
- 2011-08-31 HR HRP20221533TT patent/HRP20221533T1/hr unknown
- 2011-08-31 SI SI201132081T patent/SI4066855T1/sl unknown
- 2011-08-31 LT LTEP22174931.0T patent/LT4066856T/lt unknown
- 2011-08-31 SI SI201132119T patent/SI4226941T1/sl unknown
- 2011-08-31 RS RS20230096A patent/RS63949B1/sr unknown
- 2011-08-31 DK DK22174931.0T patent/DK4066856T3/da active
- 2011-08-31 PT PT221749310T patent/PT4066856T/pt unknown
- 2011-08-31 PT PT221747793T patent/PT4066855T/pt unknown
- 2011-08-31 SI SI201132060T patent/SI3970742T1/sl unknown
- 2011-08-31 CA CA2809851A patent/CA2809851A1/en active Pending
- 2011-08-31 HR HRP20221023TT patent/HRP20221023T1/hr unknown
- 2011-08-31 HU HUE21207859A patent/HUE058666T2/hu unknown
- 2011-08-31 SM SM20220311T patent/SMT202200311T1/it unknown
- 2011-08-31 HU HUE22174779A patent/HUE061043T2/hu unknown
- 2011-08-31 PT PT117580142T patent/PT2611461T/pt unknown
- 2011-08-31 EP EP22174779.3A patent/EP4066855B1/en active Active
- 2011-08-31 RU RU2013114362/10A patent/RU2013114362A/ru not_active Application Discontinuation
- 2011-08-31 PL PL23179901.6T patent/PL4226941T3/pl unknown
- 2011-08-31 PL PL21205422.5T patent/PL3981427T3/pl unknown
- 2011-08-31 RS RS20220501A patent/RS63315B1/sr unknown
- 2011-08-31 DK DK21205422.5T patent/DK3981427T3/da active
- 2011-08-31 US US13/819,077 patent/US20130202684A1/en not_active Abandoned
- 2011-08-31 PL PL22174779.3T patent/PL4066855T3/pl unknown
- 2011-08-31 PT PT212054225T patent/PT3981427T/pt unknown
- 2011-08-31 ES ES22174779T patent/ES2938866T3/es active Active
- 2011-08-31 ES ES23179901T patent/ES2995282T3/es active Active
- 2011-08-31 EP EP21207859.6A patent/EP3970742B1/en active Active
- 2011-08-31 HR HRP20230185TT patent/HRP20230185T8/hr unknown
- 2011-08-31 PL PL22174931.0T patent/PL4066856T3/pl unknown
- 2011-08-31 FI FIEP22174779.3T patent/FI4066855T3/fi active
- 2011-08-31 LT LTEP22174932.8T patent/LT4066857T/lt unknown
- 2011-08-31 MX MX2013002336A patent/MX2013002336A/es not_active Application Discontinuation
- 2011-08-31 RS RS20221147A patent/RS63816B1/sr unknown
- 2011-08-31 LT LTEP21205422.5T patent/LT3981427T/lt unknown
- 2011-08-31 SM SM20220290T patent/SMT202200290T1/it unknown
- 2011-08-31 PL PL11758014T patent/PL2611461T3/pl unknown
- 2011-08-31 LT LTEP23179901.6T patent/LT4226941T/lt unknown
- 2011-08-31 JP JP2013526210A patent/JP5911870B2/ja active Active
- 2011-08-31 SI SI201132059T patent/SI3981427T1/sl unknown
- 2011-08-31 EP EP22174932.8A patent/EP4066857B1/en active Active
- 2011-08-31 HR HRP20241772TT patent/HRP20241772T1/hr unknown
- 2011-08-31 LT LTEP22174779.3T patent/LT4066855T/lt unknown
- 2011-08-31 DK DK22174779.3T patent/DK4066855T3/da active
- 2011-08-31 SI SI201132075T patent/SI4066856T1/sl unknown
- 2011-08-31 AU AU2011295935A patent/AU2011295935B2/en active Active
- 2011-08-31 DK DK23179901.6T patent/DK4226941T3/da active
- 2011-08-31 RS RS20220595A patent/RS63329B1/sr unknown
- 2011-08-31 SM SM20230066T patent/SMT202300066T1/it unknown
- 2011-08-31 BR BR112013004866A patent/BR112013004866A2/pt not_active Application Discontinuation
- 2011-08-31 HU HUE22174932A patent/HUE061068T2/hu unknown
- 2011-08-31 EP EP22188690.6A patent/EP4101462A1/en active Pending
- 2011-08-31 CN CN2011800518918A patent/CN103179984A/zh active Pending
- 2011-08-31 LT LTEPPCT/US2011/050095T patent/LT2611461T/lt unknown
- 2011-08-31 RS RS20230135A patent/RS63983B1/sr unknown
- 2011-08-31 ES ES21207859T patent/ES2918649T3/es active Active
- 2011-08-31 SM SM20220223T patent/SMT202200223T1/it unknown
- 2011-08-31 EP EP21205422.5A patent/EP3981427B9/en not_active Revoked
- 2011-08-31 LT LTEP21207859.6T patent/LT3970742T/lt unknown
- 2011-08-31 SI SI201132053T patent/SI2611461T1/sl unknown
- 2011-08-31 FI FIEP23179901.6T patent/FI4226941T3/fi active
- 2011-08-31 ES ES21205422T patent/ES2918192T3/es active Active
- 2011-08-31 HU HUE21205422A patent/HUE058667T2/hu unknown
- 2011-08-31 HU HUE23179901A patent/HUE069090T2/hu unknown
- 2011-08-31 SM SM20230075T patent/SMT202300075T1/it unknown
- 2011-08-31 DK DK11758014.2T patent/DK2611461T3/da active
- 2011-08-31 DK DK22174932.8T patent/DK4066857T3/da active
-
2020
- 2020-04-01 US US16/837,115 patent/US11759422B2/en active Active
-
2022
- 2022-05-31 CY CY20221100375T patent/CY1125209T1/el unknown
- 2022-06-29 CY CY20221100448T patent/CY1125575T1/el unknown
- 2022-07-19 CY CY20221100491T patent/CY1125492T1/el unknown
-
2023
- 2023-07-25 US US18/225,749 patent/US20240216276A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3981427T3 (da) | Pegylerede liposomer til afgivelse af immunogen-kodende RNA | |
| DK4008357T3 (da) | Små liposomer til afgivelse af immunogen-kodende RNA |